Intellia Therapeutics Inc (NASDAQ:NTLA)
| 70.49 Delayed Data As of Apr 09 |  -2.59 / -3.54%Today’s Change | 12.19 Today|||52-Week Range 92.00 | +29.58% Year-to-Date |
Latest NTLA News | Press Releases
| Intellia Therapeutics Inc (NTLA) EVP, General Counsel Jose E Rivera Sold $4.2 million of Shares Apr 05 / GuruFocus News - Paid Partner Content | Here's the Holy Grail of Gene Editing Apr 02 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 73.08 |
| Today’s open | 73.02 |
| Day’s range | 70.20 - 73.65 |
| Volume | 33,260 |
| Average volume (3 months) | 1,705,352 |
| Market cap | $5.4B |
Data as of 3:59pm ET, 04/09/2021
Growth & Valuation
| Earnings growth (last year) | -13.81% |
| Earnings growth (this year) | -17.77% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +34.55% |
| P/E ratio | NM |
| Price/Sales | 52.52 |
| Price/Book | 10.05 |
Competitors
Data as of 04/09/2021
Financials
| Next reporting date | May 4, 2021 |
| EPS forecast (this quarter) | -$0.67 |
| Annual revenue (last year) | $58.0M |
| Annual profit (last year) | -$134.2M |
| Net profit margin | -231.46% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
